MA33320B1 - Derives de rifamycine - Google Patents

Derives de rifamycine

Info

Publication number
MA33320B1
MA33320B1 MA33963A MA33963A MA33320B1 MA 33320 B1 MA33320 B1 MA 33320B1 MA 33963 A MA33963 A MA 33963A MA 33963 A MA33963 A MA 33963A MA 33320 B1 MA33320 B1 MA 33320B1
Authority
MA
Morocco
Prior art keywords
alkyl
compounds
hydroxyalkyl
rifamycin derivatives
hydrogen
Prior art date
Application number
MA33963A
Other languages
Arabic (ar)
English (en)
Inventor
Giuseppe Claudio Viscomi
Manuela Campana
Mahena Folegatti
Vincenzo Cannata
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of MA33320B1 publication Critical patent/MA33320B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS COMPRENANT DES DÉRIVÉS DE RIFAMYCINE AYANT DES ACTIVITÉS ANTIBACTÉRIENNES, LES COMPOSÉS RÉPONDANT À LA FORMULE GÉNÉRALE (I) SUIVANTE DANS LAQUELLE : R REPRÉSENTE HYDROGÈNE OU ACÉTYLE; R1 ET R2 SONT INDÉPENDAMMENT CHOISIS DANS LE GROUPE CONSTITUÉ PAR HYDROGÈNE, ALKYLE EN C1-4, BENZYLOXY, MONO- ET DI(ALKYLE EN C1-3)AMINO(ALKYLE EN C1-4), ALCOXY EN C1-3, ALKYLE EN C1-4, HYDROXYMÉTHYLE, HYDROXYALKYLE EN C2-4 ET NITRO OU R1 ET R2 PRIS CONJOINTEMENT AVEC DEUX ATOMES DE CARBONE CONSÉCUTIFS DU NOYAU PYRIDINE FORMENT UN NOYAU BENZÉNIQUE ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU DEUX GROUPES MÉTHYLE OU ÉTHYLE; ET R3 REPRÉSENTE HYDROXYALKYLE EN C1-4. DE PLUS, L'INVENTION PORTE SUR DES PROCÉDÉS POUR OBTENIR CES COMPOSÉS. LES COMPOSÉS ONT UNE ACTIVITÉ ANTIBACTÉRIENNE.
MA33963A 2009-04-20 2010-03-18 Derives de rifamycine MA33320B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A000653A IT1397617B1 (it) 2009-04-20 2009-04-20 Nuovi derivati della rifamicina
PCT/IB2010/051183 WO2010122436A1 (fr) 2009-04-20 2010-03-18 Dérivés de rifamycine

Publications (1)

Publication Number Publication Date
MA33320B1 true MA33320B1 (fr) 2012-06-01

Family

ID=41228810

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33963A MA33320B1 (fr) 2009-04-20 2010-03-18 Derives de rifamycine

Country Status (27)

Country Link
US (2) US8318763B2 (fr)
EP (1) EP2421869B1 (fr)
JP (1) JP5661100B2 (fr)
KR (1) KR101555860B1 (fr)
CN (1) CN102405223A (fr)
AR (1) AR076340A1 (fr)
AU (1) AU2010240638B2 (fr)
BR (1) BRPI1005979A8 (fr)
CA (1) CA2743801C (fr)
CL (1) CL2011002597A1 (fr)
CO (1) CO6362013A2 (fr)
DK (1) DK2421869T3 (fr)
EA (1) EA020201B1 (fr)
ES (1) ES2535327T3 (fr)
HR (1) HRP20110437A2 (fr)
IL (1) IL212942A (fr)
IT (1) IT1397617B1 (fr)
MA (1) MA33320B1 (fr)
MX (1) MX338334B (fr)
NZ (1) NZ595884A (fr)
PL (1) PL2421869T3 (fr)
PT (1) PT2421869E (fr)
SG (1) SG171989A1 (fr)
TN (1) TN2011000265A1 (fr)
TW (1) TWI422372B (fr)
UA (1) UA105775C2 (fr)
WO (1) WO2010122436A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CA2886264A1 (fr) * 2012-09-12 2014-03-20 Salix Pharmaceuticals, Inc. Methodes d'administration de la rifaximine sans produire de resistance aux antibiotiques
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
KR102362719B1 (ko) * 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
CN110770244A (zh) * 2017-06-26 2020-02-07 倍尔福股份公司 吡啶并咪唑利福霉素衍生物的抗菌剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH547854A (de) * 1969-05-30 1974-04-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von antibiotika.
SU465795A3 (ru) * 1972-05-05 1975-03-30 Группо Лепетит (Фирма) Способ получени рифамицина в.
CH571064A5 (en) * 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US3847903A (en) * 1973-03-01 1974-11-12 Archifar Ind Chim Trentino Method for extracting and isolating rifamycin o from fermentation broths of rifamycins
US4267274A (en) * 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) * 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e

Also Published As

Publication number Publication date
WO2010122436A1 (fr) 2010-10-28
NZ595884A (en) 2012-12-21
US20100267654A1 (en) 2010-10-21
CA2743801C (fr) 2017-03-07
CA2743801A1 (fr) 2010-10-28
KR101555860B1 (ko) 2015-09-25
TWI422372B (zh) 2014-01-11
TW201039819A (en) 2010-11-16
UA105775C2 (uk) 2014-06-25
MX338334B (es) 2016-04-11
CL2011002597A1 (es) 2012-03-23
IL212942A0 (en) 2011-07-31
JP5661100B2 (ja) 2015-01-28
AU2010240638B2 (en) 2014-06-05
PL2421869T3 (pl) 2015-08-31
ITMI20090653A1 (it) 2010-10-21
CN102405223A (zh) 2012-04-04
EA201190216A1 (ru) 2012-02-28
CO6362013A2 (es) 2012-01-20
EA020201B1 (ru) 2014-09-30
SG171989A1 (en) 2011-07-28
BRPI1005979A8 (pt) 2017-12-26
JP2012524060A (ja) 2012-10-11
IL212942A (en) 2015-06-30
TN2011000265A1 (en) 2012-12-17
DK2421869T3 (da) 2015-06-08
EP2421869A1 (fr) 2012-02-29
KR20120014110A (ko) 2012-02-16
PT2421869E (pt) 2015-04-29
HK1163663A1 (en) 2012-09-14
AR076340A1 (es) 2011-06-01
BRPI1005979A2 (pt) 2016-02-10
HRP20110437A2 (hr) 2011-09-30
ES2535327T3 (es) 2015-05-08
US20130287692A1 (en) 2013-10-31
MX2011011026A (es) 2011-11-02
IT1397617B1 (it) 2013-01-18
US8318763B2 (en) 2012-11-27
EP2421869B1 (fr) 2015-03-11
AU2010240638A1 (en) 2010-10-28
US8765778B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
MA33320B1 (fr) Derives de rifamycine
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA34450B1 (fr) Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA34451B1 (fr) Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MA31419B1 (fr) Derives de pyridine
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
MA31738B1 (fr) Triazolo {1,5-a}quinoléines utilises comme ligands du recepteur a3 de l'adenosine
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
MA32057B1 (fr) Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique
FR2942797B1 (fr) Derives de benzothiazines, leur preparation et leur application a titre de medicaments
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
MA28211A1 (fr) Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX348601B (es) Composiciones para el cuidado oral y de la piel con base en un 3,3´-dialquil-1,1´-bifenil-2,2´-diol o un 3,3´-dialquenil-1,1´-bif enil-2,2´-diol.